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1. Introduction 
Many patients who present with acute coronary syndrome (ACS) are candidates for 
coronary artery bypass grafting (CABG). Approximately 500,000 CABG operations are 
performed each year in the United States, and many of these patients present with acute 
coronary syndrome. In the Bypass Angioplasty Revascularization Investigation (BARI) trial 
comparing CABG and percutaneous coronary intervention for coronary artery disease, 64% 
of the patients presented with unstable angina (Rosamond, Flegal et al. 2008). According to 
2007 ACC/AHA guidelines (Anderson, Adams et al. 2007), left main stenosis greater than 
50% and three-vessel coronary artery disease represent a class I indication for coronary 
artery bypass grafting in patients with unstable angina or non-ST elevation myocardial 
infarction. In addition, patients with 2-vessel coronary artery disease and either diabetes or 
left ventricular dysfunction may benefit from coronary artery bypass grafting (Class II 
recommendation). Regardless of the modality of revascularization, patients with acute 
coronary syndrome benefit from antagonists of platelet activity such as aspirin and 
clopidogrel since these agents reduce the risk of major adverse events. However, antiplatelet 
agents also increase the risk of bleeding in patients who will ultimately proceed to coronary 
artery bypass graft surgery. Usually the benefits of early initiation of antiplatelet therapy 
outweigh the risks. The purpose of this review is to summarize current antiplatelet therapy 
in acute coronary syndrome, with particular emphasis on patients who will undergo 
coronary artery bypass, and the appropriate operative strategies will be discussed. We will 
also review the current recommendations for secondary prevention after coronary artery 
bypass grafting. 
2. Antiplatelet therapy 
Platelet activation and aggregation play a critical role in the pathogenesis of coronary 
thrombosis, and antiplatelet therapy has become a central tenet of the treatment strategy in 
acute coronary syndrome. Platelet aggregation and activation can be inhibited 
pharmacologically at several points in the cascade leading up to platelet aggregation, and 
several of these antiplatelet agents are commonly used perioperatively in the setting of acute 
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coronary syndrome. Aspirin inhibits the formation of thromboxane A2 thereby preventing 
glycoprotein (Gp) IIb/IIIa-mediated activation of platelets. Ticlodipine and clopidogrel 
inhibit ADP release from platelets and thereby prevent Gp IIb/IIIa activation, and 
eptifibatide blocks GpII B/IIIa-mediated platelet aggregation. The pharmacokinetics of 
platelet inhibition and inactivation by each type of agent is of particular importance 
regarding the timing of CABG because of the bleeding risk associated with antiplatelet 
therapy. However, the timing of CABG in the setting of ACS is often flexible, with perhaps 
less than 1% of patients with ACS requiring emergent CABG (Serebruany, Malinin et al. 
2004), so much of the bleeding risk associated with antiplatelet therapy can often be 
mitigated by waiting several days before CABG is performed. 
Regardless of whether patients with ACS undergo percutaneous coronary intervention or 
CABG, the overwhelming body of evidence supports the use of antiplatelet therapy in ACS. In 
one large meta-analysis of studies of patients with ACS (Seshadri, Whitlow et al. 2002), the risk 
of serious vascular events including non-fatal myocardial infarction or stroke was reduced by 
25%. Although aspirin was associated with a significantly reduced risk of major vascular 
events, the adenosine diphosphate (ADP)-receptor antagonists ticlodipine and clopidogrel 
were associated with an additional 10-12% risk reduction. In a direct comparison of aspirin 
and clopidogrel in the randomized Clopidogrel versus Aspirin in Patients at Risk for Ischemic 
Events (CAPRIE) trial, clopidogrel was associated with an 8.7% relative reduction of risk of 
ischemic stroke, myocardial infarction, or vascular death compared with aspirin, with no 
signicant difference in the safety profiles of the two drugs (1996). Furthermore, the beneficial 
effects of aspirin and clopidogrel in ACS are additive. In the Clopidogrel in Unstable angina to 
prevent Recurrent Events (CURE) trial, unstable angina and non-ST elevation myocardial 
infarction (NSTEMI), patients taking both clopidogrel and aspirin had less chance of cardiac 
death, non-fatal MI, or stroke at 30 days and 1 year compared to those only taking aspirin 
(Yusuf, Zhao et al. 2001). Taken together, these studies all confirm that antiplatelet therapy 
with both aspirin and clopidogrel should be intitiated early in ACS. 
In patients with ST-elevation myocardial infarction (STEMI), clopidogrel in addition to 
aspirin improves outcomes. In the Clopidogrel and Metoprolol in Myocardial Infarction 
(COMMIT) trial, clopidogrel in addition to aspirin was associated with a significant 
decrease in the composite endpoint of death, reinfarction, or stroke compared to aspirin 
alone (Sabatine, Cannon et al. 2005). The Clopidogrel as Adjunctive Reperfusion Therapy- 
Thrombolysis In Myocardial Infarction (CLARITY-TIMI) compared aspirin alone to 
clopidogrel in addition to aspirin in patients with STEMI and demonstrated a 36% reduction 
in relative risk of the early composite endpoint of occlusion of the infarct-related artery, 
recurrent MI, or death, and there was a 20% relative risk reduction of the late composite 
endpoint of death from cardiovascular cause, recurrent MI, or recurrent ischemia leading to 
urgent revascularization (Sabatine, Cannon et al. 2005). Importantly, there was no increase 
in bleeding complications in either the COMMIT or the CLARITY-TIMI trial. Based on such 
compelling findings, the current AHA/ACC guidelines for patients with ACS recommend 
that aspirin and clopidogrel be given as soon as possible (Anderson, Adams et al. 2007). The 
typical loading dose for clopidogrel is 300mg or 600mg. Usually for patients undergoing 
stent placement, 600mg of clopidogrel is given, while patients who are found to be 
candidates for CABG are given 300mg of clopidogrel. 
New ADP-receptor antagonist antiplatelet agents include prasugrel and ticagrelor. Both 
decrease the relative risk of ischemic events when used with aspirin (Ebrahimi, Dyke et al. 
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2009; Wallentin, Becker et al. 2009). However, prasugrel is associated with increased risk of 
bleeding complications, especially related to CABG. In contrast, ticagrelor was not 
associated with increased risk of bleeding related to CABG. 
Several clinical trials have examined the outcomes of patients with ACS who were treated 
with antiplatelet therapy before undergoing CABG. In the CURE trial, patients who 
proceeded to CABG after receiving clopidogrel as opposed to placebo had a decreased 
relative risk of the composite endpoint of death, MI or stroke prior to CABG (RR 0.56 95% CI 
0.29-1.08, absolute risk reduction 1.8%). As long as clopidogrel was stopped 5 days prior to 
CABG there was no increase in risk of life-threatening bleeding. The CLARITY-TIMI trial 
and the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trials 
demonstrated similar improved outcomes without increased risk of bleeding in patients 
who underwent CABG after being treated with clopidogrel (Ferraris, Ferraris et al. 2005). 
3. Coronary artery bypass grafting and acute coronary syndrome 
Using antiplatelet agents in patients with ACS raises the risk of bleeding in those patients 
that undergo CABG, however several factors including the pharmacokinetic profile, 
individual patient sensitivity to the agent, and timing of the surgery determine the exact risk 
posed. Clinical trials are often difficult to compare because of varying classification of 
bleeding complications leading to differing conclusions. The Aspirin Guideline Taskforce of 
the Society of Thoracic Surgeons reviewed 21 studies examining the effect of preoperative 
aspirin on bleeding after CABG (Ebrahimi, Dyke et al. 2009). The dose of aspirin varied 
significantly between studies, so comparison of the findings is difficult. However, there 
appears to be a small increase in chest tube drainage and blood loss and a small increase in 
need for blood transfusion associated with preoperative aspirin, all of which may be dose 
related. Nonetheless, the mortality benefit of aspirin preoperatively in ACS outweighs the 
small risk of bleeding, leading to a class IIa recommendation to continue aspirin for 
urgent/emergent CABG patients. Some studies have shown an increased risk of 
perioperative bleeding in patients treated with both aspirin and ADP receptor antagonists 
such as clopidogrel who proceed to CABG (Yende and Wunderink 2001; Hongo, Ley et al. 
2002; Genoni, Tavakoli et al. 2003). Therefore, clopidogrel should be stopped for 5-7 days 
before CABG when possible (ACC/AHA class I recommendation). 
Because of the increased risk of bleeding after CABG in patients on dual antiplatelet 
therapy, one strategy would be to wait until coronary anatomy is defined on coronary 
angiography. However, this would delay antiplatelet therapy for all patients with a 
decrement in the benefit for all patients, most of whom do not end up undergoing CABG. 
The number of patients with ACS who proceed to CABG is probably between 7-14% (Bhatt, 
Roe et al. 2004; Fox, Anderson et al. 2007), and salvage CABG after failed percutaneous 
coronary intervention is relatively uncommon. The risk of bleeding after CABG, as well as 
the risk of reoperation for bleeding, overall is fairly low. Thus, the vast majority of patients 
will benefit from starting dual antiplatelet therapy early in ACS, and many patients would 
be harmed by delaying therapy. 
4. Operative strategies 
Usually CABG can be delayed in ACS to allow ADP-receptor blockers to be metabolized 
and excreted allowing platelet function to recover. If anticoagulation is critical, as is usually 
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the case in ACS, short acting anticoagulants such as unfractionated heparin and Gp IIb/IIIa 
inhibitors can be used up until shortly before going to the operative room. Patients with 
ACS who have ongoing ischemia or are hemodynamically unstable and have received ADP-
receptor antagonists may benefit from bridge percutaneous coronary intervention or intra-
aortic balloon pump insertion. An algorithm for the management of patients with ACS that 
undergo CABG is presented in Figure 1.  
 
 
Fig. 1. Algorithm or the management of patients with ACS and indications for CABG. 
Patients with ACS who are stable are observed while ADP receptor blockers are held for 5 
days prior to surgery to eliminate the increased risk of bleeding and mortality (Ferraris, 
Ferraris et al. 2005; Ebrahimi, Dyke et al. 2009). Aspirin is continued up to the time of 
surgery. If there is particular concern about the grade of coronary stenosis or evidence of 
ongoing ischemia, the patient may be continued on unfractionated heparin and/or Gp 
IIb/IIIa inhibitors up until the time of surgery. The bleeding time or platelet function time 
can be used to assess platelet function and the bleeding risk preoperatively. This may be 
useful in assessing bleeding risk and planning for CABG. The dose of clopidogrel may be 
proportional to the risk of bleeding after CABG. In patients who receive the 600 mg loading 
dose of clopidogrel, CABG should be delayed 5-7 days for the platelet function to recover. 
However, in patients who received the lower 300 mg loading dose and are maintained on 75 
mg per day of clopidogrel, CABG may be safely performed after holding clopidogrel for 1-3 
days. A logical strategy is to administer 300mg of clopidogrel in addition to aspirin at the 
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time of presentation in patients with ACS. When coronary angiography is performed, an 
additional 300mg of clopidogrel may be given if percutaneous coronary intervention is 
performed, while in those that will undergo CABG, no additional clopidogrel is given and 
low dose aspirin is continued. 
In patients with ACS and high grade left main coronary artery stenosis or left main 
equivalent who have received high dose clopidogrel or thrombolytics, insertion of an intra-
aortic balloon pump (IABP) will improve coronary perfusion and decrease cardiac demand 
by afterload reduction. Preoperative IABP insertion in these situations provides 
hemodynamic stability and reduces hospital mortality (Wiviott, Braunwald et al. 2007). 
CABG may be performed on cardiopulmonary bypass with cardioplegic arrest or off-pump 
(OPCAB). The advantages and disadvantages of OPCAB have been studied and reviewed 
extensively, yet remain controversial (Moore, Pfister et al. 2005). OPCAB avoids full 
heparinization and the systemic inflammatory response syndrome associated with 
cardiopulmonary bypass. Early studies suggested that off-pump CABG is associated with 
fewer adverse cardiovascular events and reduced early postoperative morbidity and 
mortality (Rastan, Eckenstein et al. 2006; Magee, Alexander et al. 2008). However, more 
recent data demonstrate a slightly higher rate of incomplete revascularization and a greater 
need for subsequent revascularization, as well as slightly reduced long-term mortality 
(Puskas, Kilgo et al. 2008). However, much of the outcome after OPCAB may be surgeon 
and center dependent, and this should be taken into account when formulating operative 
plans for patients with ACS undergoing CABG. 
5. Secondary prevention 
CABG for patients with ACS reduces angina, reduces the risk of myocardial infarction, 
and improves long-term survival, particularly when the internal thoracic artery is grafted 
to the left anterior descending artery (Anderson, Adams et al. 2007). However, secondary 
prevention strategies are critical for the long-term benefit of revascularization to be 
realized. Lifestyle modification such as diet modification, an exercise regimen, and 
smoking cessation are necessary. Pharmacologic secondary prevention consisting of lipid-
lowering agents, antihypertensives (primarily with beta blockers), and antiplatelet 
medications is also required to decrease the risk of progression of coronary artery disease 
and graft occlusion. A strategy for antiplatelet therapy after CABG in patients with ACS is 
presented in Figure 2. All patients should be continued on aspirin postoperatively to 
reduce the risk of vein graft occlusion (ACC/AHA class I recommendation). This also 
protects against the risk of future cardiovascular, cerebrovascular, and peripheral 
vascular ischemic events. In patients with ACS who have undergone coronary artery stent 
placement, clopidogrel is required in addition to aspirin to reduce major cardiac events 
(Muller, Buttner et al. 2000). In the CURE trial, patients with ACS treated with clopidogrel 
in addition to aspirin had decreased cardiac events, stroke and hospitalizations at 1 year 
regardless of whether they underwent PCI or CABG (Yusuf, Zhao et al. 2001). Therefore, 
in our practice, patients with ACS who undergo on-pump CABG or OPCAB are treated 
with 600mg aspirin suppository upon postoperative admission to the intensive care unit. 
When they are extubated, clopidogrel 75mg daily is administered, in addition to aspirin 
81mg daily. Dual antiplatelet therapy is continued in all patients with ACS for 9-12 
months. 
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Fig. 2. Strategy for antiplatelet therapy for secondary prevention of CAD after CABG. 
All patients with a history of a cardiovascular event should be started on a beta blocker and 
3-hydroxy-3-methylglutaryl coenzyme A (MHG –CoA) reductase inhibitors (statins) for 
secondary prevention of cardiovascular events unless otherwise contraindicated (1994; 
Sacks, Pfeffer et al. 1996; 1998). Angiotensin converting enzyme inhibitors should be 
initiated in all patients with CAD and a left ventrticular ejection fraction less than 40%, 
diabetes, hypertension, or chronic kidney disease (Smith, Allen et al. 2006). ACE inhibitors 
may be considered in lower risk patients with well-controlled risk factors. If ACE inhibitors 
are not tolerated or are contraindicated, angiotensin receptor blockers (ARBs) may be 
considered. Patients with heart failure may also benefit from ARBs. Medication compliance 
is required for successful secondary prevention and must be ensured to reap the benefits of 
revascularization. 
6. Conclusions 
Antiplatelet therapy with aspirin and clopidogrel imparts a clear benefit in major adverse 
cardiovascular events and mortality after acute coronary syndrome. Although these agents 
may pose additional bleeding risk in the small percentage of patients with ACS that proceed 
to CABG, the risk is far outweighed by the benefits, and much of the bleeding can be 
diminished by delaying CABG when possible. Short acting anticoagulants and IABP 
insertion may temporize while allowing platelet function to recover after discontinuing 
www.intechopen.com
Coronary Bypass Grafting in Acute Coronary  
Syndrome: Operative Approaches and Secondary Prevention 
 
177 
clopidogrel. Following bleeding times postoperatively can clarify the need for platelet 
transfusion in the event of bleeding.  OPCAB may have offer some benefits by avoiding full 
heparinization and avoiding the inflammatory response associated with cardiopulmonary 
bypass. Secondary prevention with antiplatelet therapy, beta blockade, lipid lowering 
therapy, and ACE inhibitors or ARBs is critical to the long term success of revascularization. 
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